Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Optimer Pharmaceuticals, Inc. (OPTR)?

Page 1 of 2

Should Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) investors track the following data?

At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite hedge fund managers can beat the market by a superb amount (see just how much).

Equally as key, positive insider trading sentiment is a second way to analyze the stock market universe. Just as you’d expect, there are plenty of stimuli for an insider to drop shares of his or her company, but just one, very clear reason why they would buy. Plenty of empirical studies have demonstrated the impressive potential of this tactic if investors understand what to do (learn more here).

Now that that’s out of the way, let’s analyze the newest info surrounding Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR).

How are hedge funds trading Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR)?

In preparation for the third quarter, a total of 15 of the hedge funds we track held long positions in this stock, a change of 36% from the previous quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were upping their stakes considerably.

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR)Out of the hedge funds we follow, James E. Flynn’s Deerfield Management had the biggest position in Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR), worth close to $43.8 million, comprising 2.1% of its total 13F portfolio. On Deerfield Management’s heels is QVT Financial, managed by Daniel Gold, which held a $23.6 million position; the fund has 1.6% of its 13F portfolio invested in the stock. Remaining hedge funds that are bullish include Matthew Halbower’s Pentwater Capital Management, Ken Griffin’s Citadel Investment Group and Sander Gerber’s Hudson Bay Capital Management.

As one would understandably expect, certain bigger names were leading the bulls’ herd. Deerfield Management, managed by James E. Flynn, initiated the most valuable position in Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR). Deerfield Management had 43.8 million invested in the company at the end of the quarter. Daniel Gold’s QVT Financial also made a $23.6 million investment in the stock during the quarter. The other funds with brand new OPTR positions are Matthew Halbower’s Pentwater Capital Management, Ken Griffin’s Citadel Investment Group, and Sander Gerber’s Hudson Bay Capital Management.

How are insiders trading Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR)?

Legal insider trading, particularly when it’s bullish, is best served when the primary stock in question has experienced transactions within the past six months. Over the last half-year time frame, Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR). These stocks are EXACT Sciences Corporation (NASDAQ:EXAS), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), and Array Biopharma Inc (NASDAQ:ARRY). This group of stocks are in the biotechnology industry and their market caps are closest to OPTR’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!